{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:51:54Z","timestamp":1787313114603,"version":"build-2736575974"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2024GXNSFBA010423"],"award-info":[{"award-number":["2024GXNSFBA010423"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2023GXNSFAA026039"],"award-info":[{"award-number":["2023GXNSFAA026039"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000611"],"award-info":[{"award-number":["32000611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32560218"],"award-info":[{"award-number":["32560218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015920","name":"Guangxi University of Science and Technology","doi-asserted-by":"publisher","award":["2023BZRC014"],"award-info":[{"award-number":["2023BZRC014"]}],"id":[{"id":"10.13039\/501100015920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cellimm.2026.105112","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:30:04Z","timestamp":1777332604000},"page":"105112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond HLA-Ia: A multidimensional framework for Neoantigen immunotherapy"],"prefix":"10.1016","volume":"425","author":[{"given":"Liurui","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2026.105112_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0015","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0020","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","article-title":"A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma","volume":"188","author":"Blass","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2026.105112_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0030","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1073\/pnas.85.7.2274","article-title":"Immunogenic (tum-) variants of mouse tumor p815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation","volume":"85","author":"De Plaen","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105112_bb0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1126\/science.8342042","article-title":"Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter","volume":"261","author":"Neefjes","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0040","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.183.4.1545","article-title":"The requirement for proteasome activity class i major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen","volume":"183","author":"Yang","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0050","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class i and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0055","first-page":"276","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0060","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","article-title":"Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction","volume":"56","author":"M\u00fcller","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2026.105112_bb0065","doi-asserted-by":"crossref","first-page":"D1152","DOI":"10.1093\/nar\/gkaf1218","article-title":"The IPD-IMGT\/HLA database: recent developments in sequence submission","volume":"54","author":"Barker","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0070","doi-asserted-by":"crossref","first-page":"D1053","DOI":"10.1093\/nar\/gkac1011","article-title":"The IPD-IMGT\/HLA database","volume":"51","author":"Barker","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/329506a0","article-title":"Structure of the human class i histocompatibility antigen, HLA-A2","volume":"329","author":"Bjorkman","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0080","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-018-07109-w","article-title":"HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome","volume":"9","author":"Illing","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0085","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0090","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2026.105112_bb0095","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/tan.12965","article-title":"New insights in HLA-E polymorphism by refined analysis of the full-length gene","volume":"89","author":"Olieslagers","year":"2017","journal-title":"Hla"},{"key":"10.1016\/j.cellimm.2026.105112_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00251-015-0880-z","article-title":"The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch","volume":"68","author":"Celik","year":"2016","journal-title":"Immunogenetics"},{"key":"10.1016\/j.cellimm.2026.105112_bb0115","doi-asserted-by":"crossref","first-page":"eaea8707","DOI":"10.1126\/sciadv.aea8707","article-title":"Unconventional CD8(+) t cell surveillance of cytomegalovirus via Qa-1\/HLA-E-restricted epitope recognition","volume":"11","author":"Reilly","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cellimm.2026.105112_bb0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, b and c","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0125","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1073\/pnas.0802736105","article-title":"Structural basis for NKG2A\/CD94 recognition of HLA-E","volume":"105","author":"Kaiser","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105112_bb0130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E: CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2026.105112_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13434","article-title":"HLA-E: immune receptor functional mechanisms revealed by structural studies","volume":"329","author":"Gillespie","year":"2025","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cellimm.2026.105112_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0145","doi-asserted-by":"crossref","first-page":"1507632","DOI":"10.3389\/fonc.2025.1507632","article-title":"Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures","volume":"15","author":"Lin","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0150","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noy200","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0155","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1158\/1078-0432.CCR-04-2588","article-title":"Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors","volume":"11","author":"Facoetti","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0160","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-12-2861","article-title":"LOH in the HLA class i region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma","volume":"19","author":"Yeung","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0165","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0175","article-title":"Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 t-cell infiltration in glioblastoma","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0180","article-title":"Hypoxia potentiates glioma-mediated immunosuppression","volume":"6","author":"Wei","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.cellimm.2026.105112_bb0185","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2026.105112_bb0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41580-024-00778-0","article-title":"Mechanisms and regulation of substrate degradation by the 26S proteasome","volume":"26","author":"Arkinson","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0200","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO precision medicine working group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0205","article-title":"Shared neoantigens for cancer immunotherapy","volume":"33","author":"Goloudina","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.cellimm.2026.105112_bb0210","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","article-title":"Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA","volume":"28","author":"Chandran","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0215","doi-asserted-by":"crossref","first-page":"eade2886","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0220","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0225","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0230","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase i trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013613","article-title":"Phase I\/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)","volume":"14","author":"Ninmer","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0240","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/0008-5472.CAN-05-1932","article-title":"Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients","volume":"66","author":"Somasundaram","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0245","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI98689","article-title":"Tumor-infiltrating BRAFV600E-specific CD4+ t cells correlated with complete clinical response in melanoma","volume":"128","author":"Veatch","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2026.105112_bb0250","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR t cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1084\/jem.20171046","article-title":"Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma t cell therapy","volume":"215","author":"Chheda","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2176\/nmc.oa.2018-0078","article-title":"EGFRvIII is expressed in cellular areas of tumor in a subset of glioblastoma","volume":"59","author":"Nozawa","year":"2019","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"10.1016\/j.cellimm.2026.105112_bb0270","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0275","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0280","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.tips.2024.10.013","article-title":"Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors","volume":"45","author":"Shah","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0285","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/1078-0432.CCR-23-3077","article-title":"Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma","volume":"30","author":"Johanns","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0290","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.cellimm.2026.105112_bb0295","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1158\/0008-5472.CAN-12-0123","article-title":"Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886","volume":"72","author":"Kim","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0300","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11060-014-1635-7","article-title":"Dendritic cell vaccination combined with temozolomide retreatment: results of a phase i trial in patients with recurrent glioblastoma multiforme","volume":"121","author":"Hunn","year":"2015","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.cellimm.2026.105112_bb0305","first-page":"0","article-title":"DIPG-32. Neoantigen heat shock protein vaccine, RHSC-DIPGVAX, is associated with increased vaccine-induced B cells and BCR\/TCR repertoire diversity in pediatric patients with diffuse midline gliomas","volume":"26","author":"Boland","year":"2024","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0310","doi-asserted-by":"crossref","unstructured":"Q. Wang, B. Hu, X. Hu, H. Kim, M. Squatrito, L. Scarpace, A.C. deCarvalho, S. Lyu, P. Li, Y. Li, F. Barthel, H.J. Cho, Y.H. Lin, N. Satani, E. Martinez-Ledesma, S. Zheng, E. Chang, C.G. Sauv\u00e9, A. Olar, Z.D. Lan, G. Finocchiaro, J.J. Phillips, M.S. Berger, K.R. Gabrusiewicz, G. Wang, E. Eskilsson, J. Hu, T. Mikkelsen, R.A. DePinho, F. Muller, A.B. Heimberger, E.P. Sulman, D.H. Nam, R.G.W. Verhaak, Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment, Cancer Cell, 32 (2017) 42\u201356.e46.","DOI":"10.1016\/j.ccell.2017.06.003"},{"key":"10.1016\/j.cellimm.2026.105112_bb0315","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13046-021-01954-2","article-title":"EMP3 mediates glioblastoma-associated macrophage infiltration to drive t cell exclusion","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0320","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0325","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system iymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0330","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","article-title":"CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature","volume":"21","author":"Louveau","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0335","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fimmu.2020.01402","article-title":"Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma","volume":"11","author":"DeCordova","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0340","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.cellimm.2026.105112_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class i antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0350","article-title":"Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers","volume":"14","author":"Lim","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0355","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1084\/jem.176.4.1083","article-title":"Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient peptide binding","volume":"176","author":"Ulbrecht","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0360","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1182\/blood-2006-06-030213","article-title":"Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation","volume":"109","author":"Coupel","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2026.105112_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/tan.70390","article-title":"HLA class ib and MICA\/MICB expression in human tissues and cell types: reshuffling immune players","volume":"106","author":"Abi-Rached","year":"2025","journal-title":"Hla"},{"key":"10.1016\/j.cellimm.2026.105112_bb0370","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","article-title":"HLA class i signal peptide polymorphism determines the level of CD94\/NKG2-HLA-E-mediated regulation of effector cell responses","volume":"24","author":"Lin","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0375","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1084\/jem.187.5.813","article-title":"Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class i signal sequence-derived peptides by CD94\/NKG2 confers protection from natural killer cell-mediated lysis","volume":"187","author":"Borrego","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0380","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.20072525","article-title":"CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class i leader sequence","volume":"205","author":"Petrie","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0385","doi-asserted-by":"crossref","first-page":"eabe9057","DOI":"10.1126\/sciimmunol.abe9057","article-title":"Natural killer cell receptors regulate responses of HLA-E-restricted t cells","volume":"6","author":"Sullivan","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.cellimm.2026.105112_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000782","article-title":"Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 t-cells with cytotoxic as well as regulatory activity","volume":"6","author":"Joosten","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cellimm.2026.105112_bb0395","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jimmun\/vkae068","article-title":"HLA-E\/peptide complexes differentially interact with NKG2A\/CD94 and t cell receptors","volume":"214","author":"Voogd","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0400","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148979","article-title":"HLA-E-restricted HIV-1-specific CD8+ t cell responses in natural infection","volume":"131","author":"Bansal","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2026.105112_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg1703","article-title":"HLA-E-restricted, Gag-specific CD8(+) t cells can suppress HIV-1 infection, offering vaccine opportunities","volume":"6","author":"Yang","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0410","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2514956122","article-title":"A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking","volume":"122","author":"He","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105112_bb0415","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2022.03.002","article-title":"Antigen presentation by MHC-E: a putative target for vaccination?","volume":"43","author":"Voogd","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0420","doi-asserted-by":"crossref","first-page":"1442783","DOI":"10.3389\/fimmu.2024.1442783","article-title":"Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and t-cell-directed immunotherapies","volume":"15","author":"Weitzen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0425","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009934","article-title":"Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in t cells and NK cells for cancer immunotherapy","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0435","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41577-025-01218-6","article-title":"Targeting MHC-E as a new strategy for vaccines and immunotherapeutics","volume":"26","author":"Fr\u00fch","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0440","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0445","doi-asserted-by":"crossref","first-page":"20240403","DOI":"10.1098\/rstb.2024.0403","article-title":"Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?","volume":"380","author":"S\u00f6derberg-Naucler","year":"2025","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0450","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 t cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2026.105112_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16112036","article-title":"Bimodal effect of NKG2A blockade on intratumoral and systemic CD8 t cell response induced by cancer vaccine","volume":"16","author":"Riva","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellimm.2026.105112_bb0460","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.20020797","article-title":"A signal peptide derived from hsp60 binds HLA-E and interferes with CD94\/NKG2A recognition","volume":"196","author":"Micha\u00eblsson","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110503","article-title":"SARS-CoV-2 nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells","volume":"38","author":"Hammer","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellimm.2026.105112_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012755","article-title":"Emerging mutation in SARS-CoV-2 facilitates escape from NK cell recognition and associates with enhanced viral fitness","volume":"20","author":"Bilev","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cellimm.2026.105112_bb0475","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","article-title":"High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation","volume":"14","author":"Huisman","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0480","doi-asserted-by":"crossref","first-page":"eadm7515","DOI":"10.1126\/sciadv.adm7515","article-title":"CD8(+) t cell targeting of tumor antigens presented by HLA-E","volume":"10","author":"Iyer","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cellimm.2026.105112_bb0485","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe9233","article-title":"Modulation of MHC-E transport by viral decoy ligands is required for RhCMV\/SIV vaccine efficacy","volume":"372","author":"Verweij","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0490","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41591-018-0130-7","article-title":"Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound","volume":"24","author":"Okoye","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0495","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.287.5455.1031","article-title":"Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40","volume":"287","author":"Tomasec","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0500","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005577","article-title":"Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia","volume":"10","author":"Haroun-Izquierdo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0505","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.3390\/ijms23169426","article-title":"Selective expansion of NKG2C+ adaptive NK cells using k562 cells expressing HLA-E","volume":"23","author":"Phan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.010","article-title":"Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor","volume":"6","author":"S\u00e6tersmoen","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.cellimm.2026.105112_bb0515","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human gamma delta t cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0520","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1063916","article-title":"Regulation of cutaneous malignancy by gammadelta t cells","volume":"294","author":"Girardi","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0525","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1126\/science.2528206","article-title":"Structure and specificity of a class II MHC alloreactive gamma delta t cell receptor heterodimer","volume":"245","author":"Matis","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0530","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212525","article-title":"A CMV-induced adaptive human v\u03b41+ \u03b3\u03b4 t cell clone recognizes HLA-DR","volume":"219","author":"Deseke","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0535","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.4049\/jimmunol.153.7.3093","article-title":"Identification of a novel HLA-B27 subtype by restriction analysis of a cytotoxic gamma delta t cell clone","volume":"153","author":"Del Porto","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav4036","article-title":"Generation and molecular recognition of melanoma-associated antigen-specific human \u03b3\u03b4 t cells","volume":"3","author":"Benveniste","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0545","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.immuni.2013.11.001","article-title":"Crystal structure of v\u03b41 t cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human \u03b3\u03b4 t cells","volume":"39","author":"Luoma","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2026.105112_bb0550","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta t cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2026.105112_bb0555","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u0393\u03b4 t cells are effectors of immunotherapy in cancers with HLA class i defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0560","doi-asserted-by":"crossref","first-page":"2138152","DOI":"10.1080\/2162402X.2022.2138152","article-title":"Human allogenic \u03b3\u03b4 t cells kill patient-derived glioblastoma cells expressing high levels of DNAM-1 ligands","volume":"11","author":"Choi","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2026.105112_bb0565","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.1158\/1078-0432.CCR-19-0375","article-title":"NKG2D controls natural reactivity of V\u03b39V\u03b42 t lymphocytes against mesenchymal glioblastoma cells","volume":"25","author":"Chauvin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41590-025-02397-z","article-title":"\u0393\u03b4 t cell-derived IL-4 initiates CD8(+) t cell immunity","volume":"27","author":"Le","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0575","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s43018-025-01007-z","article-title":"IL-17A-secreting \u03b3\u03b4 t cells promote resistance to CDK4\/CDK6 inhibitors in HR(+)HER2(\u2212) breast cancer via CX3CR1(+) macrophages","volume":"6","author":"Petroni","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cellimm.2026.105112_bb0580","doi-asserted-by":"crossref","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","article-title":"Murine CD27(\u2212) v\u03b36(+) \u03b3\u03b4 t cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages","volume":"111","author":"Rei","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105112_bb0585","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fimmu.2018.00658","article-title":"Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta t cell functions through IL-15 secretion","volume":"9","author":"Van Acker","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0590","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-019-0666-2","article-title":"Best practices for bioinformatic characterization of neoantigens for clinical utility","volume":"11","author":"Richters","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0595","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral t cell responses in phase ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2026.105112_bb0600","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class i molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0605","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2020.01803","article-title":"Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs","volume":"11","author":"Springer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0610","doi-asserted-by":"crossref","first-page":"W134","DOI":"10.1093\/nar\/gkad275","article-title":"DeepNeo: a webserver for predicting immunogenic neoantigens","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0615","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/annonc\/mdy022","article-title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","volume":"29","author":"Kim","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0620","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac192","article-title":"HLAncPred: a method for predicting promiscuous non-classical HLA binding sites","volume":"23","author":"Dhall","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.cellimm.2026.105112_bb0625","doi-asserted-by":"crossref","first-page":"2023255","DOI":"10.1080\/2162402X.2021.2023255","article-title":"Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF\u00ae09b, in patients with metastatic melanoma","volume":"11","author":"M\u00f8rk","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2026.105112_bb0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1478201","article-title":"LRMAHpan: a novel tool for multi-allelic HLA presentation prediction using ResNet-based and LSTM-based neural networks","volume":"15","author":"Mi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0635","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf582","article-title":"A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class i-restricted neoantigens","volume":"26","author":"Zhang","year":"2025","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.cellimm.2026.105112_bb0640","first-page":"39","article-title":"Structural and functional aspects of the blood-brain barrier","volume":"61","author":"Begley","year":"2003","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.cellimm.2026.105112_bb0645","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1461-5347(98)00117-5","article-title":"Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems","volume":"2","author":"Pardridge","year":"1999","journal-title":"Pharm. Sci. Technol. Today."},{"key":"10.1016\/j.cellimm.2026.105112_bb0650","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrn1824","article-title":"Astrocyte-endothelial interactions at the blood-brain barrier","volume":"7","author":"Abbott","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0655","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/pr.57.2.4","article-title":"The blood-brain barrier\/neurovascular unit in health and disease","volume":"57","author":"Hawkins","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cellimm.2026.105112_bb0660","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1038\/s41467-023-38703-2","article-title":"Antigen recognition detains CD8(+) t cells at the blood-brain barrier and contributes to its breakdown","volume":"14","author":"Aydin","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0665","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/joim.13469","article-title":"Central nervous system zoning: how brain barriers establish subdivisions for CNS immune privilege and immune surveillance","volume":"292","author":"Proulx","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cellimm.2026.105112_bb0670","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.cellimm.2026.105112_bb0675","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","article-title":"\u0393\u03b4 t cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0680","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102454","article-title":"The abundance of tumor-infiltrating CD8(+) tissue resident memory T lymphocytes correlates with patient survival in glioblastoma","volume":"10","author":"La Manna","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cellimm.2026.105112_bb0685","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 iymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2026.105112_bb0690","doi-asserted-by":"crossref","first-page":"v213","DOI":"10.1093\/neuonc\/noaf201.0843","article-title":"IMMU-45. Allogeneic B7-H3 \u03b3\u03b4 CAR-T cells effectively eradicate glioblastoma in preclinical models","volume":"27","author":"Choi","year":"2025","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.cellimm.2026.105112_bb0695","article-title":"Rational design and organoid-based evaluation of a cocktail CAR-\u03b3\u03b4 t cell therapy for heterogeneous glioblastoma","volume":"12","author":"Zhu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.cellimm.2026.105112_bb0700","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","article-title":"Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies","volume":"37","author":"Ding","year":"2020","journal-title":"Mater Today (Kidlington)"},{"key":"10.1016\/j.cellimm.2026.105112_bb0705","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cellimm.2026.105112_bb0710","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(23)00112-2","article-title":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","volume":"24","author":"Sonabend","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0715","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0720","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12035-023-03365-0","article-title":"Exosomes: promising delivery tools for overcoming Blood-Brain Barrier and glioblastoma therapy","volume":"60","author":"Khatami","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0725","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathmechdis-051122-110348","article-title":"Role of the microenvironment in glioma pathogenesis","volume":"19","author":"Jayaram","year":"2024","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0730","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jnen\/64.6.523","article-title":"HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo","volume":"64","author":"Wischhusen","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0735","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/eji.1830271111","article-title":"Control of self-reactive cytotoxic t lymphocytes expressing gamma delta t cell receptors by natural killer inhibitory receptors","volume":"27","author":"Halary","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105112_bb0740","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in parkinson's disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105112_bb0745","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/bbmt.1999.v5.pm10465102","article-title":"Graft-facilitating doses of ex vivo activated gammadelta t cells do not cause lethal murine graft-vs.-host disease","volume":"5","author":"Drobyski","year":"1999","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:21:34Z","timestamp":1783056094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874926000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":149,"alternative-id":["S0008874926000523"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105112","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond HLA-Ia: A multidimensional framework for Neoantigen immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105112"}}